YUKI GOSEI KOGYO CO.,LTD. Logo

YUKI GOSEI KOGYO CO.,LTD.

Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.

4531 | T

Overview

Corporate Details

ISIN(s):
JP3946400003
LEI:
Country:
Japan
Address:
中央区日本橋人形町三丁目10番4号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Yuki Gosei Kogyo Co., Ltd. is a chemical manufacturing company established in 1947. Specializing in the field of organic synthesis, the company engages in the research, development, manufacturing, and marketing of fine chemical products. Its core product portfolio includes amino acids (such as Glycine), pharmaceuticals, active pharmaceutical ingredients (APIs), and various chemical intermediates. Utilizing its unique and proprietary technologies, Yuki Gosei Kogyo serves both Japanese and international markets, providing high-quality products for various industrial applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 02:35
Report Publication Announcement
確認書
Japanese 8.9 KB
2025-11-13 02:32
Interim Report
半期報告書-第106期(2025/04/01-2026/03/31)
Japanese 184.9 KB
2025-06-24 04:13
Post-Annual General Meeting Information
臨時報告書
Japanese 26.5 KB
2025-06-19 06:08
Governance Information
内部統制報告書-第105期(2024/04/01-2025/03/31)
Japanese 23.0 KB
2025-06-19 06:07
Registration Form
確認書
Japanese 8.8 KB
2025-06-19 06:05
Annual Report
有価証券報告書-第105期(2024/04/01-2025/03/31)
Japanese 724.5 KB
2025-01-08 02:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.8 KB
2024-12-04 02:01
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.8 KB
2024-11-13 02:17
Interim Report
確認書
Japanese 8.8 KB
2024-11-13 02:15
Interim Report
半期報告書-第105期(2024/04/01-2025/03/31)
Japanese 188.9 KB
2024-11-06 02:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.3 KB
2024-10-03 09:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.1 KB
2024-09-04 03:21
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2024-08-06 04:12
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB
2024-06-25 02:36
Post-Annual General Meeting Information
臨時報告書
Japanese 26.8 KB

Automate Your Workflow. Get a real-time feed of all YUKI GOSEI KOGYO CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for YUKI GOSEI KOGYO CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for YUKI GOSEI KOGYO CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGEN CORP Logo
Provides diagnostic tests and genomics services for food, animal, and agricultural safety.
United States of America
NEOG
NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS

Talk to a Data Expert

Have a question? We'll get back to you promptly.